Literature DB >> 27884399

Cardiovascular events and death in Japanese patients with chronic kidney disease.

Kenichi Tanaka1, Tsuyoshi Watanabe2, Ayano Takeuchi3, Yasuo Ohashi4, Kosaku Nitta5, Tadao Akizawa6, Seiichi Matsuo7, Enyu Imai8, Hirofumi Makino9, Akira Hishida10.   

Abstract

The incidence of cardiovascular disease (CVD) is higher in patients with chronic kidney disease (CKD) than in the general population, and the risk of CVD increases with reductions in renal function. However, the incidence of CVD in Japanese patients with CKD has not been sufficiently investigated. To measure this we conducted the Chronic Kidney Disease Japan Cohort (CKD-JAC) Study over four years in 2,966 Japanese patients with CKD to examine the incidence of CVD and all-cause death. These patients had an estimated glomerular filtration rate (eGFR) of 10-59 ml/min/1.73 m2, were under nephrologist care, and pooled from 17 medical institutions in Japan. At the median follow-up of 3.9 years, 69 patients had died, 217 had cardiovascular events, and 514 started maintenance dialysis therapy. The incidences of cardiovascular events were 11.9, 19.1, 25.0, and 39.4 per 1,000 person-years at eGFRs of 45-59, 30-44, 15-29, and under 15 ml/min/1.73 m2, respectively. The adjusted Cox proportional hazards models showed that the risk of cardiovascular events increased as the eGFR decreased, with a significant difference only between CKD stage G5 (eGFR: under 15 ml/min/1.73 m2) and CKD stage G3a (eGFR: 45-59 ml/min/1.73 m2) (hazard ratio 3.16, 95% confidence interval 1.28 to 7.76). Thus, the risk of CVD and all-cause death was related to the decrease in eGFR, but not necessarily elevated in proportion to progression of the CKD stage in Japanese patients with predialysis CKD under a nephrologist's care.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CKD-JAC; cardiovascular disease; chronic kidney disease; cohort study

Mesh:

Substances:

Year:  2016        PMID: 27884399     DOI: 10.1016/j.kint.2016.09.015

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  37 in total

1.  Trajectories of kidney function and associated factors among community-dwelling older Japanese: a 16-year longitudinal study.

Authors:  Sho Kaito; Yu Taniguchi; Akihiko Kitamura; Satoshi Seino; Hidenori Amano; Yuri Yokoyama; Hiroshi Fukuda; Hirohide Yokokawa; Yoshinori Fujiwara; Shoji Shinkai; Toshio Naito
Journal:  Clin Exp Nephrol       Date:  2019-12-26       Impact factor: 2.801

2.  Blood pressure control in chronic kidney disease according to underlying renal disease: the Fukushima CKD cohort.

Authors:  Aya Nakajima; Kenichi Tanaka; Hirotaka Saito; Tsuyoshi Iwasaki; Akira Oda; Makoto Kanno; Michio Shimabukuro; Koichi Asahi; Tsuyoshi Watanabe; Junichiro James Kazama
Journal:  Clin Exp Nephrol       Date:  2019-12-26       Impact factor: 2.801

3.  Sleep Quality and Sleep Duration with CKD are Associated with Progression to ESKD.

Authors:  Ryohei Yamamoto; Maki Shinzawa; Yoshitaka Isaka; Etsuko Yamakoshi; Enyu Imai; Yasuo Ohashi; Akira Hishida
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-15       Impact factor: 8.237

4.  Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease.

Authors:  Yuji Sato; Shouichi Fujimoto; Tsuneo Konta; Kunitoshi Iseki; Toshiki Moriyama; Kunihiro Yamagata; Kazuhiko Tsuruya; Ichiei Narita; Masahide Kondo; Masato Kasahara; Yugo Shibagaki; Koichi Asahi; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2017-08-16       Impact factor: 2.801

5.  Longitudinal Follow-Up and Outcomes for Chinese Patients with Stage 1-4 Chronic Kidney Disease.

Authors:  Jinwei Wang; Jicheng Lv; Kevin He; Fang Wang; Bixia Gao; Ming-Hui Zhao; Luxia Zhang
Journal:  Kidney Dis (Basel)       Date:  2021-10-27

6.  Association of Polypharmacy with Kidney Disease Progression in Adults with CKD.

Authors:  Hiroshi Kimura; Kenichi Tanaka; Hirotaka Saito; Tsuyoshi Iwasaki; Akira Oda; Shuhei Watanabe; Makoto Kanno; Michio Shimabukuro; Koichi Asahi; Tsuyoshi Watanabe; Junichiro James Kazama
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-15       Impact factor: 8.237

7.  Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.

Authors:  Tadao Akizawa; Keiko Tanaka-Amino; Tetsuro Otsuka; Yusuke Yamaguchi
Journal:  Am J Nephrol       Date:  2021-10-08       Impact factor: 3.754

8.  Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.

Authors:  Terumasa Hayashi; Shoichi Maruyama; Masaomi Nangaku; Ichiei Narita; Hideki Hirakata; Kenichiro Tanabe; Satoshi Morita; Yoshiharu Tsubakihara; Enyu Imai; Tadao Akizawa
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-03       Impact factor: 8.237

9.  Cardiovascular disease in kidney transplant recipients: Japan Academic Consortium of Kidney Transplantation (JACK) cohort study.

Authors:  Masayoshi Okumi; Yoichi Kakuta; Kohei Unagami; Ryoichi Maenosono; Katsunori Miyake; Junpei Iizuka; Toshio Takagi; Hideki Ishida; Kazunari Tanabe
Journal:  Clin Exp Nephrol       Date:  2017-11-20       Impact factor: 2.801

10.  Dipstick proteinuria and all-cause mortality among the general population.

Authors:  Kunitoshi Iseki; Tsuneo Konta; Koichi Asahi; Kunihiro Yamagata; Shouichi Fujimoto; Kazuhiko Tsuruya; Ichiei Narita; Masato Kasahara; Yugo Shibagaki; Toshiki Moriyama; Masahide Kondo; Chiho Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2018-06-05       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.